The outlook for Severe Hypertriglyceridemia treatments is promising. Various clinical trials have been fairly positive in terms of safety and limited evaluations of efficacy. The results of these studies are encouraging further investigation into the basic physiology of the disease, as well as the mechanisms of effective prevention and reversal of arteriosclerosis.
DelveInsight’s “Severe Hypertriglyceridemia (SHTG) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Severe Hypertriglyceridemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Severe Hypertriglyceridemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Severe Hypertriglyceridemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Severe Hypertriglyceridemia (SHTG): An Overview
High levels of triglycerides are the characteristic condition for the disease called Hypertriglyceridemia. Patients with severe hypertriglyceridemia (SHTG) have triglyceride levels more than three times the normal level. It leads to multiple serious conditions, including cardiovascular disease (CVD) and acute pancreatitis.
High triglycerides may contribute to hardening of the arteries or thickening of the artery walls (arteriosclerosis) — which increases the risk of stroke, heart attack, and heart disease. Factors like genetic disorders, obesity, untreated diabetes, and certain medications can lead to the development of SHTG.
Severe hypertriglyceridemia is broadly categorized into two categories, primary disorders and secondary disorders. The genetic disorders come under primary disorder and the latter is commonly because of other underlying diseases and secondary factors. The molecular basis for primary hypertriglyceridemia has been found in less than 5% of cases — and for secondary cases, no genetic susceptibility component that is reproducible
SHTG does not have noticeable symptoms, however, individuals with extremely high levels of triglycerides (greater than 2,000 mg/dL) can experience recurrent abdominal pain, nausea, vomiting, xanthomas (yellow-colored bumps on the skin), and acute pancreatitis.
Hypertriglyceridemia is diagnosed by doing blood tests, to check very low-density lipoprotein (VLDL) and triglyceride levels. Blood tests show a mild to moderate increase in triglycerides (about 200 to 500 mg/dL).
Severe Hypertriglyceridemia (SHTG) Market Key Facts
-
Among the 7MM, the US consistently captured the highest Severe Hypertriglyceridemia market of about USD 1.4 billion in 2022, which is anticipated to grow during the forecast period.
-
In 2022, EU4 and the UK captured an estimated USD 687 million, and Japan covered a market of about USD 325 million.
-
Among the forecasted emerging therapies, ARO-APOC3 is expected to capture the highest market in the 7MM by 2032.
-
In 2022, the total diagnosed prevalent cases of Hypertriglyceridemia (HTG) were 69 million, and for Severe Hypertriglyceridemia (SHTG) were 3 million cases in the 7MM, which is expected to rise by 2032.
-
The United States showed the highest diagnosed prevalent population of HTG compared to other 7MM countries. As per DelveInsight’s estimates, the country alone accounts for nearly 44% of total diagnosed prevalent cases, for HTG, in the 7MM countries.
-
The severity-specific diagnosed prevalent cases of HTG are segmented based on their triglyceride levels into mild, moderate, and severe cases. These cases were observed to be highest for moderate cases, followed by mild and severe cases.
-
In 2022, among the 7MM, the etiology-specific distribution of severe hypertriglyceridemia was done, and the number of diagnosed prevalent cases of primary and secondary SHTG was found to be 1.5 and 2 million, respectively.
-
EU4 and the UK countries accounted for nearly 1.4 million diagnosed prevalent cases of Severe Hypertriglyceridemia in 2022. Of these cases, 0.36 million cases were estimated in Germany accounting for the highest number of diagnosed prevalent cases of SHTG in Europe.
-
Japan accounted for 16% of the total diagnosed prevalent cases of Severe Hypertriglyceridemia i.e. in the 7MM in 2022, with approximately 0.5 million cases.
Severe Hypertriglyceridemia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Severe Hypertriglyceridemia pipeline therapies. It also thoroughly assesses the Severe Hypertriglyceridemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Severe Hypertriglyceridemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Severe Hypertriglyceridemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Severe Hypertriglyceridemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Severe Hypertriglyceridemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Severe Hypertriglyceridemia Epidemiology, Segmented as –
-
Prevalent Cases of Hypertriglyceridemia in the 7MM [2019–2032]
-
Etiology-specific Diagnosed Prevalent Cases of Severe Hypertriglyceridemia in the 7MM [2019–2032]
-
Diagnosed Prevalent Cases of Hypertriglyceridemia in the 7MM [2019–2032]
-
Severity-specific Diagnosed Prevalent Cases of Hypertriglyceridemia in the 7MM [2019–2032]
Severe Hypertriglyceridemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Severe Hypertriglyceridemia market or expected to be launched during the study period. The analysis covers the Severe Hypertriglyceridemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Severe Hypertriglyceridemia drugs based on their sale and market share.
The report also covers the Severe Hypertriglyceridemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Severe Hypertriglyceridemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Severe Hypertriglyceridemia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market
Severe Hypertriglyceridemia Therapeutics Analysis
Hypertriglyceridemia is causally linked to cardiovascular disease and pancreatitis. Lifestyle modifications Hypertriglyceridemia (HTG) is defined as fasting triglycerides (TGs) ≥150 mg/dL, and when the level of TG exceeds >500 mg/dL the condition turns into severe hypertriglyceridemia (SHTG).
For the treatment of HTG, popular guidelines such as AHA/ACC lipid treatment guidelines recommend addressing and treating lifestyle factors, secondary factors such as diabetes mellitus, chronic liver or kidney disease, and/or nephrotic syndrome, hypothyroidism, and medications that increase triglycerides. If serum triglycerides remain elevated even after optimizing these factors, pharmacological therapies are to be considered. The goal of drug treatment is to reduce the level of triglyceride and to reduce the risk of pancreatitis and cardiovascular disease in patients with severe hypertriglyceridemia.
To treat SHTG, most of the guidelines recommend treatment with Statins, fibrates, omega-3 fatty acids, or niacin. However, these recommendations are largely based on observational studies.
Several major pharma and biotech companies are developing therapies for Severe Hypertriglyceridemia. Currently, Ionis Pharmaceuticals, Inc. is leading the therapeutics market with its Severe Hypertriglyceridemia drug candidates in the most advanced stage of clinical development. The pipeline for SHTG consists of some key assets, i.e., Olezarsen (ApoC-III), ARO-APOC3, and Pegozafermin (BIO89-100), among others which after successful launch will lead to market growth during the forecast period.
Severe Hypertriglyceridemia Companies Actively Working in the Therapeutics Market Include
-
Arrowhead Pharmaceuticals
-
Ionis Pharmaceuticals, Inc.
-
89bio, Inc.
-
Regeneron Pharmaceuticals
-
Kowa Research Institute, Inc.
-
Mochida Pharmaceutical
-
Acasti Pharma Inc.
-
NorthSea Therapeutics
-
Matinas BioPharma
And Many Others
Emerging and Marketed Severe Hypertriglyceridemia Therapies Covered in the Report Include:
-
ARO-APOC3: Arrowhead Pharmaceuticals
-
Olezarsen: Ionis Pharmaceuticals
-
VASCEPA/VAZKEPA: Amarin Corporation
-
NST-1024 (SEFA 1024): NorthSea Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Severe Hypertriglyceridemia Competitive Intelligence Analysis
4. Severe Hypertriglyceridemia Market Overview at a Glance
5. Severe Hypertriglyceridemia Disease Background and Overview
6. Severe Hypertriglyceridemia Patient Journey
7. Severe Hypertriglyceridemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Severe Hypertriglyceridemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Severe Hypertriglyceridemia Unmet Needs
10. Key Endpoints of Severe Hypertriglyceridemia Treatment
11. Severe Hypertriglyceridemia Marketed Therapies
12. Severe Hypertriglyceridemia Emerging Drugs and Latest Therapeutic Advances
13. Severe Hypertriglyceridemia Seven Major Market Analysis
14. Attribute Analysis
15. Severe Hypertriglyceridemia Market Outlook (In US, EU5, and Japan)
16. Severe Hypertriglyceridemia Companies Active in the Market
17. Severe Hypertriglyceridemia Access and Reimbursement Overview
18. KOL Views on the Severe Hypertriglyceridemia Market
19. Severe Hypertriglyceridemia Market Drivers
20. Severe Hypertriglyceridemia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Complicated Intra-Abdominal Infections Market
“Complicated Intra-Abdominal Infections Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Complicated Intra-Abdominal Infections market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Complicated Intra-Abdominal Infections market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices